Overview

An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
This study is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy, safety and convenience of using repaglinide (NovoNorm®) in type 2 diabetes management in routine clinical practice.
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Repaglinide